Table 1.
Definitions | Morphological features | Biochemical features | |
---|---|---|---|
Apoptosis | Type of RCD initiated by perturbation of the extracellular or intracellular microenvironment; Demarcated by mitochondrial outer membrane permeabilization (MOMP); Precipitated by executioner caspases, mainly caspase3 (CASP3). |
Rounding-up of the cell; Retraction of pseudopods; Reduction of cellular and nuclear volume (pyknosis); Nuclear fragmentation (karyorrhexis); Minor modification of cytoplasmic organelles; Plasma membrane blebbing; Engulfment by resident phagocytes in vivo. |
Release of mitochondrial intermembrane space ‘IMS’ proteins; Respiratory chain inhibition. |
MTP-driven Necrosis | Specific form of RCD triggered by perturbations of the intracellular microenvironment and relying on cyclophilin D (CYPD). | Rupture of plasma Membrane; Cytoplasm: cytoplasmic swelling. (Oncosis): Swelling of cytoplasmic organelles; Moderate chromatin condensation. |
Caspase inhibition; NADPH oxidase activation; Neutrophil extracellular traps (NETs) release (in some instances). |
Pyroptosis | A type of RCD that critically depends on the formation of plasma membrane pores by members of the gasdermin protein family; Often (but not always) as a consequence of inflammatory caspase activation. |
The early membrane rupture of pyroptotic cells exposes the inner leaflet of the plasma membrane to the extracellular surface; Transmembrane ion fluxes; Cytoplasmic swelling; Osmotic lysis of the cell. |
Caspase-1 activation; Caspase-7 activation; Secretion of IL-1β and IL18. |
Ferroptosis | A form of RCD initiated by oxidative perturbations of the intracellular microenvironment that is under constitutive control by GPX4 and can be inhibited by iron chelators and lipophilic antioxidants. | Normal nuclei and shrinking mitochondria that show increased membrane density and outer mitochondrial membrane rupture. | Iron and ROS accumulation; Inhibition of system xc−; With decreased cystine uptake; GSH depletion and increased; NAPDH oxidation Release of arachidonic acid mediators. |